MRI contrast developer Epix Medical has completed enrollment for two phase III clinical trials of its MS-325 agent. The two trials will evaluate MS-325 for the detection of vascular disease in the pedal and renal arteries, according to the Cambridge, MA-based vendor. Epix said it's on track to submit a new drug application (NDA) to the Food and Drug Administration in the fall.
By AuntMinnie.com staff writersFebruary 4, 2003
Related Reading
Epix losses continue, MS-325 enrollment completed, October 25, 2002
Epix net loss widens, delays MS-325 NDA, July 26, 2002
Epix shows first-quarter loss, April 24, 2002
Epix to raise $30 million, January 16, 2002
Epix revenues climb in Q3, October 19, 2001
Copyright © 2003 AuntMinnie.com
